Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NevGold Announces Up To 53.7% Antimony, And Fourteen Samples Over 2% Antimony, From Surface Sampling On Pre-Strip Dump
TomaGold Completes Extension Drilling Program at Berrigan Mine and Launches Major Prospecting and Geophysical Survey Campaign Across its Chibougamau Properties
